Regeneron develops and sells biologic medicines, most visibly Eylea for retinal disease, Dupixent (co-developed with Sanofi) for atopic dermatitis and asthma, and Libtayo for cancer immunotherapy. Its edge is a repeatable antibody platform, VelocImmune and the wider Regeneron Genetics Center, which has produced a steady run of approvals rather than a single hit, and Dupixent's expanding label is now the main engine of revenue growth. The near-term question is how fast Dupixent and newer launches can offset Eylea's erosion from biosimilars, and the answer will show up in quarterly sales and pipeline readouts. At 19.7 times trailing earnings and 14.5 times forward, the stock trades at a discount to its growth, with revenue up 16.7% and an operating margin of 33.1%. The score of 71 out of 100 and the 44.5% gross margin suggest a profitable franchise, but the Eylea exposure and reliance on one blockbuster are the points to test in a deeper look.
Plain-English pros, cons, and what to watch. Pro feature.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.
Trades are only made public after a delay. We show the delay so you know how old the news is.
Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.
| Date | Type | New | Previous | Price |
|---|---|---|---|---|
| 20 Oct 2026, 16:04 CEST | Fair value | $847 | $1175 | $782 |
| 20 Oct 2026, 16:04 CEST | Rating | Fairly valued | first publication | $782 |
| 16 Oct 2026, 00:00 CEST | ACCE price target | $895 | $875 | $796 |
| 16 Oct 2026, 00:00 CEST | Fair value | $1175 | $1148 | $778 |
| 11 Oct 2026, 00:00 CEST | Fair value | $1148 | $1086 | $747 |
| 5 Oct 2026, 00:00 CEST | Fair value | $1086 | $1097 | $735 |
| 29 Sept 2026, 00:00 CEST | Fair value | $1097 | $1126 | $788 |
| 22 Sept 2026, 00:00 CEST | Fair value | $1126 | $1142 | $785 |
| 19 Sept 2026, 00:00 CEST | Fair value | $1142 | $1127 | $789 |
| 15 Sept 2026, 00:00 CEST | Fair value | $1127 | $1147 | $781 |
Answered from Regeneron Pharmaceuticals Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.
| Company | Price | Fair value | vs fair value | P/E | ROE | Quality | Score |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals Inc. Common Stock | $805.02 | $847 | 5% below | 19.9x | 14.0% | 86 | 71 |
| MRNA Moderna Inc. Common Stock | $202.63 | - | - | - | -39.0% | 31 | 46 |
| CSL.AX CSL | A$196.14 | A$160 | 23% above | - | -15.8% | 52 | 52 |
| UCB.BR UCB | €259.10 | €143 | 81% above | 24.1x | 20.6% | 95 | 76 |
| ARGX argenx SE American Depositary Shares | $875.76 | $399 | 119% above | 30.3x | 23.6% | 91 | 74 |
| VRTX Vertex Pharmaceuticals Incorporated Common Stock | $535.17 | $327 | 64% above | 30.5x | 23.5% | 91 | 68 |
| ONC BeOne Medicines Ltd. American Depositary Shares | $382.27 | $152 | 151% above | 69.1x | 14.7% | 76 | 69 |
Where REGN ranks against its sector peers on each metric.